Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Yamamoto, Takaya ^a   Jingu, Keiichi ^a   Shirata, Yuko ^a   Koto, Masashi ^b   Matsushita, Haruo ^a   Sugawara, Toshiyuki ^a   Kubozono, Masaki ^a   Umezawa, Rei ^a   Abe, Keiko ^a   Kadoya, Noriyuki ^a   Ishikawa, Youjirou ^a   Kozumi, Maiko ^a   Takahashi, Noriyoshi ^a   Takeda, Ken ^c   Takai, Yoshihiro ^d  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

Author keywords

Metastatic lung tumor; Oligometastasis; Primary lung cancer; Prognostic factor; SBRT; Stereotactic radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER SIZE; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PNEUMONIA; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; CANCER STAGING; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOSURGERY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84902750449     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-464     Document Type: Article

References (29)

1. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076. 10.1001/jama.2010.261, 2907644, 20233825.
2. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584. 10.1200/JCO.2008.19.6386, 19255320.
3. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013, 31(11):1384-1390. 10.1200/JCO.2012.45.9651, 23460715.
4. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010, 28(35):5153-5159. 10.1200/JCO.2010.30.0731, 21041709.
5. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012, 84(5):1060-1070. 10.1016/j.ijrobp.2012.07.2354, 3776428, 22975611.
6. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010, 40:107-111. 10.1093/jjco/hyp167, 2813545, 20047860.
7. Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K. Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulm Med 2012, 2012:454107. 3472526, 23094150.
8. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2(7 Suppl 3):S94-S100.
9. Dunlap NE, Larner JM, Read PW, Kozower BD, Lau CL, Sheng K, Jones DR. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010, 140:583-589. 10.1016/j.jtcvs.2010.01.046, 20478576.
10. Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, Verdries D, Everaert H, Christian N, De Ridder M, Storme G. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys 2011, 80(5):1343-1349. 10.1016/j.ijrobp.2010.04.056, 20708849.
11. Takeda A, Yokosuka N, Ohashi T, Kunieda E, Fujii H, Aoki Y, Sanuki N, Koike N, Ozawa Y. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol 2011, 101(2):291-297. 10.1016/j.radonc.2011.08.008, 21889224.
12. Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011, 101(2):255-259. 10.1016/j.radonc.2011.05.033, 21641064.
13. Hamamoto Y, Kataoka M, Yamashita M, Nogami N, Sugawara Y, Kozuki T, Sawada S, Suehisa H, Shinohara S, Nakajima N, Shinkai T. Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors. Jpn J Radiol 2012, 30(5):430-434. 10.1007/s11604-012-0071-x, 22450903.
14. Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Wilbert J, Xiao Y, Belderbos J. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 2012, 7(9):1382-1393. 10.1097/JTO.0b013e318260e00d, 22843086.
15. Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Ciammella P, Franco P, Mantovani C, Borasio P, Scagliotti GV, Ragona R. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 2010, 68:72-77. 10.1016/j.lungcan.2009.05.007, 19556022.
16. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 2012, 7:152. 10.1186/1748-717X-7-152, 3444889, 22963661.
17. Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78(4):1033-1039. 10.1016/j.ijrobp.2009.09.081, 20472359.
18. Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, Britton KR, Jingu K, Takai K, Mitsuya M, Nemoto K, Yamada S. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007, 85(3):429-434. 10.1016/j.radonc.2007.10.017, 18022720.
19. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2(8):563-572. 10.1038/nrc865, 12154349.
20. Cifone MA, Fidler IJ. Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci U S A 1981, 78(11):6949-6952. 10.1073/pnas.78.11.6949, 349170, 6947269.
21. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005, 63(1):25-36. 10.1016/j.ijrobp.2005.04.049, 16111569.
22. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1889, 8(2):98-101.
23. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011, 128(11):2527-2535. 10.1002/ijc.26031, 3075088, 21365651.
24. Comen E, Norton L. Self-seeding in cancer. Recent Results Cancer Res 2012, 195:13-23. 10.1007/978-3-642-28160-0_2, 22527491.
25. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986, 70(1):163-169.
26. Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman RD. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 2011, 8(7):405-416. 10.1038/nrclinonc.2011.75, 21606970.
27. Cho S, Song IH, Yang HC, Kim K, Jheon S. Predictive factors for node metastasis in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg 2013, 96(1):239-245. 10.1016/j.athoracsur.2013.03.050, 23673071.
28. Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. J Thorac Oncol 2010, 5(2):206-210. 10.1097/JTO.0b013e3181c422be, 19901852.
29. van Bodegom PC, Wagenaar SS, Corrin B, Baak JP, Berkel J, Vanderschueren RG. Second primary lung cancer: importance of long term follow up. Thorax 1989, 44(10):788-793. 10.1136/thx.44.10.788, 1020843, 2595619.